EPISODE 038
ReVision Optics built it – a corneal inlay capable of correcting presbyopia. The FDA approved it sooner than expected. Now the company needs to build it into a successful private-pay business.
Podcast Guest
John Kilcoyne
President & CEO
ReVision Optics
Mr. Kilcoyne brings more than 33 years of experience in the medical device market to ReVision Optics. He understands the needs of both patients and physicians combined with an ability to lead companies from the development to commercialization stage as well as through mergers and Initial Public Offerings (IPO). Prior to joining ReVision Optics, Mr. Kilcoyne has lead three organizations, two of which were acquired, creating shareholder value in excess of $500M. In 2005, he took Micrus Endovascular public (NASDAQ) then successfully led the company until its acquisition by Johnson and Johnson in 2010. Mr. Kilcoyne currently serves on the AdvaMed Board of Directors and AdvaMed/Accel Board of Directors and is the current Chair of the AdvaMed Ophthalmic Sector.
Meet Our Host
Geoff Pardo
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.